1-18 of 18
Yoshiaki Ogawa
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Nirav N. Shah, Pier Luigi Zinzani, Michael L. Wang, Sunita D. Nasta, Ewa Lech-Maranda, Yoshiaki Ogawa, Bita Fakhri, Bryone Kuss, Kaname Miyashita, Krish Patel, Catherine C. Coombs, Shuo Ma, Manish Patel, Minal A. Barve, Benoit Tessoulin, Anastasios Stathis, Won Seog Kim, Daisuke Ennishi, Daigo Hashimoto, Kensuke Kojima, Andrew D. Zelenetz, Jonathon B. Cohen, Julie M. Vose, Kami J. Maddocks, Talha Munir, Fangfang Sun, Faith Bian, Donald E. Tsai, Paolo Abada, Chan Y. Cheah
Journal: Blood
Blood (2023) 142 (Supplement 1): 3026.
https://doi.org/10.1182/blood-2023-181309
Published: 2023
Journal Articles

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

Naval Daver, Joshua F. Zeidner, Junichiro Yuda, Justin M. Watts, Mark J. Levis, Kentaro Fukushima, Takayuki Ikezoe, Yoshiaki Ogawa, Joseph Brandwein, Eunice S. Wang, Yasushi Miyazaki, Timothy Pardee, Naoko Hosono, Takahiro Shima, Hisayuki Yokoyama, Noboru Asada, Joseph Jurcic, Hongliang Cai, Akinobu Watanabe, Matthew Hitron, Emily Brooks, Bo Xu, Jatin Shah, Hagop M. Kantarjian, Harry P. Erba
Journal: Blood
Blood (2023) 142 (Supplement 1): 2911.
https://doi.org/10.1182/blood-2023-179252
Published: 2023
Journal Articles

Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)

Naval Daver, Takayuki Ikezoe, Justin Watts, Naoko Hosono, Yoshiaki Ogawa, Yasushi Miyazaki, Harry P. Erba, John Affinito, Emily Brooks, Ken Eguchi, Hongliang Cai, Bo Xu, Jay Stoudemire, Matthew Hitron, Akinobu Watanabe, Philip Komarnitsky, Junichiro Yuda
Journal: Blood
Blood (2022) 140 (Supplement 1): 3371–3372.
https://doi.org/10.1182/blood-2022-167674
Published: 2022
Journal Articles

Overcoming Tyrosine Kinase Inhibitor Resistance to SEPT9-ABL1 Chimeric Fusion Protein Using CRM1 Inhibitors

Hidetsugu Kawai, MD, Hiromichi Matsushita, MD PhD, Yoshiaki Ogawa, MD, Hiroshi Kawada, MDPhD, Kiyoshi Ando, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1234.
https://doi.org/10.1182/blood.V130.Suppl_1.1234.1234
Published: 2017
Journal Articles

NKG2D Gene Polymorphism Is Associated with Disease Control of Chronic Myeloid Leukemia By Dasatinib

Ryujiro Hara, Makoto Onizuka, MD PhD, Erika Matsusita, Eri Kikkawa, Yoshihiko Nakamura, Daisuke Ogiya, Hiromichi Murayama, Ken Omachi, Yukari Shirasugi, MD PhD, Yoshiaki Ogawa, Hiroshi Kawada, Kiyoshi Ando, MDPhD
Journal: Blood
Blood (2016) 128 (22): 3091.
https://doi.org/10.1182/blood.V128.22.3091.3091
Published: 2016
Journal Articles

Phase 2 Study of Lenalidomide in Combination with Low-Dose Dexamethasone in Japanese Transplantation-Ineligible Newly-Diagnosed Multiple Myeloma Patients

Takaaki Chou, Atsushi Shinagawa, MD PhD, Toshiki Uchida, MD, Masafumi Taniwaki, MD PhD, Hirokazu Hirata, MD PhD, Kenichi Ishizawa, MD PhD, Kosei Matsue, MD PhD, Yoshiaki Ogawa, MD, Takayuki Shimizu, MD PhD, Maki Otsuka, MD, Morio Matsumoto, MD, Shinsuke Iida, Yasuhito Terui, MD PhD, Itaru Matsumura, Takashi Ikeda, MD PhD, Naoki Takezako, MD PhD, Yumi Ogaki, MD, Shuichi Midorikawa, MD, Vanessa Houck, Annette Ervin-Haynes, Kenshi Suzuki, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3452.
https://doi.org/10.1182/blood.V124.21.3452.3452
Published: 2014
Journal Articles

MM-004: A Phase 1, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, Efficacy, and Pharmacokinetics of Pomalidomide Alone or in Combination with Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma in Japan

Shinsuke Iida, Hiromi Iwasaki, MD PhD, Takaaki Chou, Kensei Tobonai, Kazutaka Sunami, Yoshiaki Ogawa, MD, Mari Kurihara, Shuichi Midorikawa, Mohamed H. Zaki, MD, Thomas Doerr, MSc, Kosei Matsue
Journal: Blood
Blood (2014) 124 (21): 2107.
https://doi.org/10.1182/blood.V124.21.2107.2107
Published: 2014
Journal Articles

A Multicenter Phase I Study of the Humanized Anti-CD19 Monoclonal Antibody, MEDI-551, in Patients with Relapsed or Refractory B-Cell Lymphoma and Multiple Myeloma

Michinori Ogura, MD PhD, Kiyoshi Ando, MD, Naokuni Uike, Yoshiaki Ogawa, MD, Toshiki Uchida, MD, Yasunobu Abe, MD, Takanobu Morishita, MD, Minoru Kojima, MD PhD, Ilseung Choi, MD, Katsuro Yagawa, MD, Yuki Yokoi, Jun Okamura, MD
Journal: Blood
Blood (2014) 124 (21): 1756.
https://doi.org/10.1182/blood.V124.21.1756.1756
Published: 2014
Journal Articles

Expression of CD56 Is an Independent Prognostic Factor to Predict Relapse in Acute Myeloid Leukemia with t(8;21): Results of Japan Adult Leukemia Study Group (JALSG) AML97 Protocol.

Noriyoshi Iriyama, Yoshihiro Hatta, MD, PhD, Jin Takeuchi, MD, PhD, Yoshiaki Ogawa, MD, PhD, Shigeki Ohtake, MD, PhD, Toru Sakura, MD, PhD, Kinuko Mitani, MD, Fumihiro Ishida, MD, Masatomo Takahashi, MD, Tomoya Maeda, MD, PhD, Tohru Izumi, MD, Hisashi Sakamaki, MD, Shuichi Miyawaki, MD, Sumihisa Honda, PhD, Yasushi Miyazaki, MD, PhD, Tomohiko Taki, MD, PhD, Masafumi Taniwaki, MD, PhD, Tomoki Naoe, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 2511.
https://doi.org/10.1182/blood.V120.21.2511.2511
Published: 2012
Journal Articles

ACE Polymorphism and Idiopathic Pneumonia Syndrome After Allogeneic Stem Cell Transplantation

Makoto Onizuka, MD, PhD, Mitsuki Miyamono, M.D., Shinichiro Machida, M.D., Toyosaki Masako, M.D. Ph.D, Yoshiaki Ogawa, M.D. Ph.D, Hiroshi Kawada, MD, PhD, Kiyoshi Ando, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1943.
https://doi.org/10.1182/blood.V120.21.1943.1943
Published: 2012
Journal Articles

Association of PML Expression with Chemotherapy-Resistance In Multiple Myeloma Cells

Daisuke Ohgiya, MD, Makoto Onizuka, MD, PhD, Hiromichi Matsushita, MD, PhD, Naoya Nakamura, MD, PhD, Hiroshi Kawada, MD, PhD, Yoshiaki Ogawa, MD, PhD, Kiyoshi Ando, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 2959.
https://doi.org/10.1182/blood.V116.21.2959.2959
Published: 2010
Journal Articles

A Clinical Pharmacology and Exploratory Study of Azacitidine Administered Subcutaneously or Intravenously In Japanese Patients with Myelodysplastic Syndrome

Yukio Kobayashi, MD, PhD, Michinori Ogura, MD, PhD, Kiyoshi Ando, MD, PhD, Kensei Tobinai, MD, PhD, Toshiki Uchida, MD, PhD, Yoshiaki Ogawa, MD, PhD, Takayuki Ishikawa, MD, PhD, Haruhiko Ohashi, MD, PhD, Tomoko Hata, MD, PhD, Noriko Usui, MD, PhD, Masafumi Taniwaki, MD, PhD, Kazunori Ohnishi, MD, PhD, Hideki Akiyama, MD, PhD, Keiya Ozawa, MD, PhD, Kazuma Ohyashiki, MD, PhD, Shinichiro Okamoto, MD, PhD, Akihiro Tomita, MD, PhD, Shinji Nakao, MD, PhD, Tomomitsu Hotta, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 4964.
https://doi.org/10.1182/blood.V116.21.4964.4964
Published: 2010
Journal Articles

Allogeneic Stem Cell Transplantation (Allo-SCT) in Adults with Acute Myelogenous Leukemia (AML). Final Analysis of JALSG AML97 Study

Hisashi Sakamaki, M.D., Shuichi Miyawaki, M.D., Shigeki Ohtake, M.D., Nobuhiko Emi, M.D., Fumiharu Yagasaki, MD, Kinuko Mitani, M.D., Shin Matsuda, M.D., Yuuji Kishimoto, M.D., Yasushi Miyazaki, MD, PhD, Norio Asou, M.D., Masatomo Takahashi, M.D., Yoshiaki Ogawa, Sumihisa Honda, Ph.D., Ryuzo Ohno
Journal: Blood
Blood (2008) 112 (11): 347.
https://doi.org/10.1182/blood.V112.11.347.347
Published: 2008
Journal Articles

Preferential Hypermethylation of the DKK-1 Promoter in Core-Binding Factor Leukaemia.

Rikio Suzuki, MD, Makoto Onizuka, M.D., Minoru Kojima, M.D., Masako Shimada, M.D., Satomi Fukagawa, M.D., Kosuke Tsuboi, M.D., Hiroyuki Kobayashi, Ph.D, Ayumi Shintani, Ph.D, Yoshiaki Ogawa, Ph.D, Hiroshi Kawada, Ph.D, Tomomitsu Hotta, Ph.D, Kiyoshi Ando, Ph.D
Journal: Blood
Blood (2007) 110 (11): 4136.
https://doi.org/10.1182/blood.V110.11.4136.4136
Published: 2007
Journal Articles

Clinical Significance of FLT3/ITD and NPM1 Mutation in Acute Myeloid Leukemia (AML).

Rikio Suzuki, Makoto Onizuka, Masako Shimada, Yasunobu Iwaki, Hiroshi Kawada, Yoshiaki Ogawa, Tomomitsu Hotta, Kiyoshi Ando
Journal: Blood
Blood (2006) 108 (11): 4442.
https://doi.org/10.1182/blood.V108.11.4442.4442
Published: 2006
Journal Articles

Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Bortezomib (B) in Patients (pts) with Relapsed Multiple Myeloma (MM): A Phase I/II Study in Japan.

Kensei Tobinai, MD, Takashi Watanabe, MD, Yoshiaki Ogawa, MD, Michinori Ogura, MD, Yasuo Morishima, MD, Hironobu Minami, MD, Kuniaki Itoh, MD, Tomomitsu Hotta, MD
Journal: Blood
Blood (2006) 108 (11): 5106.
https://doi.org/10.1182/blood.V108.11.5106.5106
Published: 2006
Journal Articles

Postremission Treatment with Chemotherapy or Allogeneic Stem Cell Transplantation (Allo-SCT) in Adults with Acute Myeloid Leukemia (AML) -JALSG AML-97 Trial-.

Hisashi Sakamaki, M.D., Shuichi Miyawaki, M.D., Shigeki Ohtake, M.D., Fumiharu Yagasaki, M.D., Kinuko Mitani, M.D., Shin Matsuda, M.D., Yuji Kishimoto, M.D., Yasushi Miyazaki, M.D., Norio Asou, M.D., Yoshiaki Ogawa, M.D., Sumihisa Honda, Ph.D., Ryuzo Ohno, M.D.
Journal: Blood
Blood (2004) 104 (11): 2298.
https://doi.org/10.1182/blood.V104.11.2298.2298
Published: 2004
Journal Articles

Postremission Therapy in Adult Acute Myeloid Leukemia (AML): A Randomized Comparison of Intensified Consolidation Therapy without Maintenance Therapy Against Conventional Consolidation with Maintenance Therapy -JALSG AML-97 Trial-.

Shuichi Miyawaki, M.D., Hisashi Sakamaki, M.D., Shigeki Ohtake, M.D., Fumiharu Yagasaki, M.D., Kinuko Mitani, M.D., Shin Matsuda, M.D., Yuji Kishimoto, M.D., Yasushi Miyazaki, M.D., Norio Asou, M.D., Yoshiaki Ogawa, M.D., Sumihisa Honda, M.D., Ryuzo Ohno, M.D.
Journal: Blood
Blood (2004) 104 (11): 868.
https://doi.org/10.1182/blood.V104.11.868.868
Published: 2004